Cooperative phase Ii study of spansule tegafur (SF-SP)
Taguchi, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(2): 319-326
1984
ISSN/ISBN: 0385-0684 PMID: 6421250 Document Number: 241236
A phase II study of oral administration of SF-SP alone was conducted in 187 patients with advanced cancers involving 34 institutions in Kinki area. CR was observed in one case of breast cancer, and PR in 29 cases. In 7 responders, response durations of 6 months or more were observed. The drug was effective against colo-rectal, in particular, gastric and breast cancer. No serious toxicity was observed.
Document emailed within 1 workday
Related Documents
Ibayashi, J. 1984: Cooperative phase Ii study of releasing tegafur (SF-SP) against advanced digestive cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(7): 1414-1419Kamiya, O.; Hoshino, A.; Ohara, K.; Nagata, K.; Kojima, T.; Sugihara, T.; Yamada, M.; Suzuki, M.; Kimura, K.; Fujii, S. 1983: Pharmacokinetics and a phase i study of tegafur-uracil enterogranules in cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(12): 2565-2572
Arima, S.; Ohsato, K.; Hisatsugu, T.; Shimura, H. 1994: Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer European Journal of Surgery 160(4): 227-232
Nakamori, S.; Endo, W.; Ozato, H.; Shibata, T.; Takeda, Y.; Tohno, K.; Hasuike, Y.; Masutani, S.; Morimoto, T.; Doki, Y.; Mori, M.; Monden, M. 2011: Multicenter phase Ii study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 789-792
Yokoyama, A.; Nakai, Y.; Yoneda, S.; Kurita, Y.; Niitani, H.; Taguchi, T. 1996: A late phase Ii study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase Ii Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(12): 1681-1688
Rosenthal, S.; Harris, D.T.; Horton, J.; Glick, J.H. 1980: Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 64(10-11): 1115-1117
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Kimura, K. 1987: A phase Ii study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(8): 2475-2481
Ettinger, D.S.; Finkelstein, D.M.; Harper, G.R.; Ruckdeschel, J.C.; Chang, A.Y.; Camacho, F.J.; Marsh, J.C.; Silber, R.; Wolter, J.M. 1985: Phase Ii study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study Cancer Treatment Reports 69(9): 1033-1034
Boros, L.; Tsiatis, A.A.; Neiman, R.S.; Mann, R.B.; Glick, J.H. 1986: Phase Ii Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma Cancer Treatment Reports 70(7): 917-918
Nomura, Y.; Abe, O.; Tominaga, T.; Tashiro, H.; Hisamatsu, K.; Enomoto, K.; Fujiwara, K.; Imoto, S.; Ando, J.; Hayashi, K. 1994: Phase i study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 189-197
Lee, D.; Perry, E. 1991: Case study: a cooperative research agreement for Navy cooperative engagement technology development Proceedings of the Technology Transfer Society Annual Meeting International Symposium and exhibit: 6TH) 108-112
1995: Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone Zhonghua nei ke za zhi 34(9): 599-602
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Tominaga, T.; Nomura, Y.; Adachi, I.; Aoyama, H.; Nagao, K.; Mitsuyama, S.; Nakamura, Y.; Ogita, M.; Sano, M.; Takashima, S. 1994: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 809-816
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Metelitsa, V.I.; Filatova, N.P. 1991: The results of the comparative study of nadolol, propranolol, prazosin and hydrochlorothiazide in patients with arterial hypertension in a 12-month stepped-plan treatment (cooperative research). The Working Group of the Cooperative Program to Study New Preparations in the Prevention of Arterial Hypertension. I. The research protocol and results of monotherapy Terapevticheskii Arkhiv 63(8): 30-34
Moertel, C.G.; Lavin, P.T. 1979: Phase II-IIi chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group Cancer Treatment Reports 63(11-12): 1863-1869
Tomita, M.; Ishikawa, H.; Hirano, T.; Nakagoe, T.; Shimizu, T.; Kusano, H.; Ifuku, M. 1992: Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(5): 671-676
Carli, M.; Perilongo, G.; di Montezemolo, L.C.; De Bernardi, B.; Ceci, A.; Paolucci, G.; Pianca, C.; Calculli, G.; Di Tullio, M.T.; Grotto, P. 1987: Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group Cancer Treatment Reports 71(5): 525-527